Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress
Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled “Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC” has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in …
Read more on News-Medical-Net
Categories: Breast Cancer Chemotherapy Tags: cancer, capecitabine, Congress, Data, gastrointestinal, Metastatic, perifosine, presented
Keryx Biopharmaceuticals’ perifosine receives FDA Fast Track Designation
Keryx Biopharmaceuticals’ perifosine receives FDA Fast Track Designation
Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company’s novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: Biopharmaceuticals', Designation, fast, Keryx, perifosine, receives, track